Lupin Looks To Next Generation In Narcolepsy With Tentative US Xywav Nod
Indian Firm Also Eligible To Move On First-Generation Xyrem – But Has Not Done So
Executive Summary
Lupin may enjoy 180 days of market exclusivity for its proposed generic to Jazz’s next-generation Xywav treatment for sleep disorders.
You may also be interested in...
Generic Spiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.
Hikma Continues To Mull Potential To Go Alone On Xyrem
Hikma’s recently installed CEO Riad Mishlawi told a packed room at the recent Jefferies 2024 London Healthcare Conference that Hikma had not reached a decision on pursuing its Xyrem ANDA product.
gSpiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat